BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive COVID-19 vaccine approval in Europe was reassuring for a new technology and likely predictive of the decision in the U.S., the analyst tells investors in a research note. The firm is boosting its probability of success in both markets following the decision by 10%, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics: Buy Rating Affirmed on EU Approval and Promising Clinical Data for Kostaive Vaccine
- Arcturus Therapeutics and CSL’s Kostaive COVID-19 vaccine approved in Europe
- CSL, Arcturus Therapeutics announce European Commission approval for Kostaive
- Arcturus Therapeutics appoints Moncef Slaoui as chair designate
- Arcturus Therapeutics initiated with a Buy at BTIG